This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

About JANUVIA® (sitagliptin)

Updated on 15/03/2018

DIABETES
Image of people over 65 with type 2 diabetes enjoying life

What is JANUVIA?

JANUVIA is a once daily DPP-4 inhibitor for the treatment of type 2 diabetes (T2DM) in adults. JANUVIA is often prescribed in combination with metformin when diet and exercise plus metformin is not achieving the glycaemic control that people need.2

With a wide range of indications in T2DM, JANUVIA is suitable for many different people.2



JANUVIA
Monotherapy (oral) If metformin is contraindicated or not tolerated
Dual therapy (oral) Add on to metformin
Add on to SU
Add on to TZD
Triple therapy (oral) Add on to metformin + SU
Add on to metformin + TZD

If your patient is currently on metformin + DPP-4i, a SGLT-2i agent can be added in line with the relevant SGLT-2i SPCs.3-5

JANUVIA is not licensed for patients <18 years of age2

How does JANUVIA help people with T2DM?

People can feel concerned about their diabetes progressing to a new stage.6

If they are uncontrolled on metformin and you are considering prescribing a DPP-4 inhibitor, JANUVIA offers proven efficacy in HbA1c reductions,7 long-term maintenance8 and an established safety profile.9

JANUVIA effectively reduces blood glucose7

When a person with T2DM is struggling to reach their target HbA1c levels, it can be worrying for both them and their healthcare provider.

In combination with metformin, JANUVIA has been shown to help people reduce their HbA1c levels. After a year of treatment, JANUVIA plus metformin showed similar reductions in blood glucose to a SU plus metformin, in people from a varied HbA1c baseline.7

HbA1c reductions observed at week 52 in all patients, including those ≥65 years old Graph showing mean HbA<sub>1c</sub> reduction from baseline at week 52 in a population including patients aged 65 and over

Adapted from Nauck et al, 2007

Study design

JANUVIA can help people with T2DM take control for longer8

A real world study found that people treated with JANUVIA plus metformin maintained their treatment without modification* for significantly longer than those using an SU plus metformin.8

*The main reason for treatment modification in both groups was insufficient efficacy. Treatment modification was defined as any discontinuation of a drug or addition of, or switch to, a new drug. Changes in dose were not considered a treatment modification8

JANUVIA plus metformin offers prolonged HbA1c control vs SU plus metformin8

Graph showing median time of treatment maintenance for JANUVIA plus metformin compared with SU plus metformin

Adapted from Valensi et al, 2015

Study design

Related content

 

References

  1. MSD data on file, DIAB-1237427-0000.
  2. JANUVIA Summary of Product Characteristics.
  3. Canagliflozin Summary of Product Characteristics.
  4. Dapagliflozin Summary of Product Characteristics.
  5. Empagliflozin Summary of Product Characteristics.
  6. Quandt SA et al. J Appl Gerontol. 2013;32(7):783-803.
  7. Nauck MA et al. Diabetes Obes Metab. 2007;9(2):194-205.
  8. Valensi P et al. Diabetes Metab. 2015;41(3)231-238.
  9. Green JB et al. N Engl J Med. 2015;373(3):232-242.

Supporting documentation

100 mg
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

50 mg
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

25 mg
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

DIAB-1247350-0025 | Date of Preparation: March 2018